| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1024329817 |
| P356 | DOI | 10.1038/NPJVACCINES.2016.21 |
| P932 | PMC publication ID | 5707885 |
| P698 | PubMed publication ID | 29263859 |
| P50 | author | David B. Weiner | Q67465894 |
| Kate E. Broderick | Q87200293 | ||
| Niranjan Y Sardesai | Q57551755 | ||
| Trina Racine | Q59146337 | ||
| Bryan D Griffin | Q65555413 | ||
| Gary P. Kobinger | Q66679700 | ||
| P2093 | author name string | Brian Lee | |
| J Joseph Kim | |||
| Karuppiah Muthumani | |||
| Jingjing Jiang | |||
| Stephanie A Booth | |||
| Jian Yan | |||
| Charles C Reed | |||
| Joel N Maslow | |||
| Amir S Khan | |||
| Matthew P Morrow | |||
| Christopher Chung | |||
| Kenneth E Ugen | |||
| Young K Park | |||
| Stephanie Ramos | |||
| Emma L Reuschel | |||
| Laurent Humeau | |||
| Sangya Agarwal | |||
| Kimberly A Kraynyak | |||
| Sagar B Kudchodkar | |||
| Elizabeth K Duperret | |||
| Hyeree Choi | |||
| Amelia Anne Keaton | |||
| Yinho K Kim | |||
| P2860 | cites work | Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007 | Q22241244 |
| Zika Virus in the Americas — Yet Another Arbovirus Threat | Q22248116 | ||
| Zika Virus Outbreak on Yap Island, Federated States of Micronesia | Q22250881 | ||
| Zika virus in Brazil and macular atrophy in a child with microcephaly | Q22330676 | ||
| Zika Virus, French Polynesia, South Pacific, 2013 | Q22330743 | ||
| Zika Virus Associated with Microcephaly | Q22683189 | ||
| Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study | Q23012849 | ||
| A statistically defined endpoint titer determination method for immunoassays. | Q51646874 | ||
| Characterization of a Novel Murine Model to Study Zika Virus | Q23667364 | ||
| Zika virus outbreak: reproductive health and rights in Latin America | Q24247100 | ||
| Concern over Zika virus grips the world | Q24247107 | ||
| Zika Virus and Microcephaly | Q24247108 | ||
| Proving Zika link to birth defects poses huge challenge | Q24247110 | ||
| Zika virus: Brazil's surge in small-headed babies questioned by report | Q24247125 | ||
| In response | Q24261130 | ||
| Zika virus | Q24261193 | ||
| A Mouse Model of Zika Virus Pathogenesis | Q24261408 | ||
| Zika virus: History, emergence, biology, and prospects for control | Q24261421 | ||
| Structural basis of potent Zika–dengue virus antibody cross-neutralization | Q24740325 | ||
| Vaccine protection against Zika virus from Brazil | Q25165129 | ||
| Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys | Q26248722 | ||
| West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays | Q27469785 | ||
| Recognition determinants of broadly neutralizing human antibodies against dengue viruses | Q27697333 | ||
| Zika virus outbreak in the Americas: the need for novel mosquito control methods | Q29035831 | ||
| Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy | Q35898318 | ||
| Optimized in vivo transfer of small interfering RNA targeting dermal tissue using in vivo surface electroporation. | Q36053828 | ||
| A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates | Q36069589 | ||
| Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses. | Q36228884 | ||
| Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b tri | Q36954152 | ||
| Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. | Q40479018 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| Zika virus | Q202864 | ||
| pathogenesis | Q372016 | ||
| active immunization | Q3425478 | ||
| Zika fever vaccine | Q24657950 | ||
| Zika virus infection | Q27043680 | ||
| P5008 | on focus list of Wikimedia project | WikiProject Zika Corpus | Q54439832 |
| P304 | page(s) | 16021 | |
| P577 | publication date | 2016-11-10 | |
| P1433 | published in | NPJ Vaccines | Q30275609 |
| P1476 | title | In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine | |
| P478 | volume | 1 |
| Q61053708 | A 'Furry-Tale' of Zika Virus Infection: What Have We Learned from Animal Models? |
| Q64075108 | A DNA Vaccine Encoding the VAA Gene of Induces a Protective Immune Response in Flounder |
| Q93101098 | A Gorilla Adenovirus-Based Vaccine against Zika Virus Induces Durable Immunity and Confers Protection in Pregnancy |
| Q56341976 | A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika |
| Q59245616 | A Recombinant Subunit Based Zika Virus Vaccine Is Efficacious in Non-human Primates |
| Q56000955 | A VSV-based Zika virus vaccine protects mice from lethal challenge |
| Q38157807 | Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue |
| Q56337689 | Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge |
| Q60193818 | Amphiphilic block copolymer delivery of a DNA vaccine against Zika virus |
| Q57050781 | Assay Challenges for Emerging Infectious Diseases: The Zika Experience |
| Q89900645 | Complete Protection in Macaques Conferred by Purified Inactivated Zika Vaccine: Defining a Correlate of Protection |
| Q55024075 | Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation. |
| Q38158576 | Current views on Zika virus vaccine development |
| Q30855414 | DNA vaccination protects mice against Zika virus-induced damage to the testes |
| Q91664048 | DNA vaccines: prime time is now |
| Q92247111 | Designed DNA-Encoded IL-36 Gamma Acts as a Potent Molecular Adjuvant Enhancing Zika Synthetic DNA Vaccine-Induced Immunity and Protection in a Lethal Challenge Model |
| Q55426158 | Developing Zika vaccines: the lessons for disease X. |
| Q47551875 | Development of Zika Virus Vaccines |
| Q98613812 | Development of a potent Zika virus vaccine using self-amplifying messenger RNA |
| Q60300678 | Efficacy of a T Cell-Biased Adenovirus Vector as a Zika Virus Vaccine |
| Q91576851 | Emerging infectious disease laboratory and diagnostic preparedness to accelerate vaccine development |
| Q47570091 | Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic |
| Q98578994 | Enhanced effect of modified Zika virus E antigen on the immunogenicity of DNA vaccine |
| Q94523117 | Evaluating Zika Virus Pathogenesis in Immunocompromised Mice |
| Q56000988 | Evolution of Two Major Zika Virus Lineages: Implications for Pathology, Immune Response, and Vaccine Development |
| Q59245612 | Fast Tracks and Roadblocks for Zika Vaccines |
| Q90000423 | Glycosylated diphyllin as a broad-spectrum antiviral agent against Zika virus |
| Q63248499 | IL-1 receptor antagonist therapy mitigates placental dysfunction and perinatal injury following Zika virus infection |
| Q94948311 | Immune-profiling of ZIKV-infected patients identifies a distinct function of plasmacytoid dendritic cells for immune cross-regulation |
| Q38157106 | Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques |
| Q63248475 | In Vivo Delivery of a DNA-Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus |
| Q56000963 | Incorporation of NS1 and prM/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E protein |
| Q92593502 | Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses |
| Q92641857 | Intradermal Synthetic DNA Vaccination Generates Leishmania-Specific T Cells in the Skin and Protection against Leishmania major |
| Q96022982 | Lipid Nanoparticle Formulation Increases Efficiency of DNA-Vectored Vaccines/Immunoprophylaxis in Animals Including Transchromosomic Bovines |
| Q40049416 | Modified mRNA Vaccines Protect against Zika Virus Infection |
| Q57072744 | New Vaccine Technologies to Combat Outbreak Situations |
| Q47548181 | Niclosamide rescues microcephaly in a humanized in vivo model of Zika infection using human induced neural stem cells |
| Q47558305 | Nonhuman Primate Models of Zika Virus Infection, Immunity, and Therapeutic Development |
| Q100437402 | Passive immunisation of convalescent human anti-Zika plasma protects against challenge with New World Zika virus in cynomolgus macaques |
| Q63248478 | Pre-Clinical Pregnancy Models for Evaluating Zika Vaccines |
| Q48504993 | Pregnancy and infection: using disease pathogenesis to inform vaccine strategy |
| Q45323630 | Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials |
| Q61795502 | Protective immunity by an engineered DNA vaccine for Mayaro virus |
| Q58602667 | Purified Inactivated Zika Vaccine Candidates Afford Protection against Lethal Challenge in Mice |
| Q51336164 | Rapid response to an emerging infectious disease - Lessons learned from development of a synthetic DNA vaccine targeting Zika virus. |
| Q59245656 | Recent Advances in Zika Virus Vaccines |
| Q51782806 | Recombinant Zika virus envelope protein elicited protective immunity against Zika virus in immunocompetent mice. |
| Q58099567 | Research Models and Tools for the Identification of Antivirals and Therapeutics against Zika Virus Infection |
| Q41924763 | Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report. |
| Q51336389 | The immunology of Zika Virus. |
| Q93078517 | Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go |
| Q91741475 | Two Is Better Than One: Evidence for T-Cell Cross-Protection Between Dengue and Zika and Implications on Vaccine Design |
| Q29571224 | Vaccination strategies against Zika virus |
| Q38157833 | Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease |
| Q38156536 | Vaccines for Emerging Infectious Diseases: lessons from MERS coronavirus and Zika virus |
| Q92130293 | Zika Vaccine Development-Current Progress and Challenges for the Future |
| Q47006432 | Zika Virus Vaccine Development |
| Q58742686 | Zika Virus Vaccines: Challenges and Perspectives |
| Q94523111 | Zika Virus: A Brief History and Review of Its Pathogenesis Rediscovered |
| Q32183208 | Zika Virus: Recent Advances towards the Development of Vaccines and Therapeutics |
| Q47168453 | Zika vaccine candidates progress through nonclinical development and enter clinical trials |
| Q45324313 | Zika virus infection of first-trimester human placentas: utility of an explant model of replication to evaluate correlates of immune protection ex vivo |
| Q50020968 | Zika virus outbreak: a review of neurological complications, diagnosis, and treatment options. |
| Q28656365 | Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination |
| Q54558329 | Zika virus vaccines: immune response, current status, and future challenges. |
| Q56343708 | Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization |
Search more.